Antidiabetogenic action of glucagon‐like peptide‐1 related to administration relative to meal intake in subjects with type 2 diabetes
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Gutniak MK, Svartberg J, Hellström PM, Holst JJ, Adner N, Ahrén B (Södersjukhuset, Stockholm, Sweden; University Hospital of Tromsö, Tromsö, Norge; Karolinska Hospital, Stockholm, Sweden; PANUM Institute, Copenhagen, Denmark; and Lund University, Lund, Sweden). Antidiabetogenic action of GLP‐1 related to administration relative to meal intake in subjects with type 2 diabetes. J Intern Med 2001; 250: 81–87. Objective. To establish the antidiabetogenic effect of glucagon‐like peptide‐1 (GLP‐1) when differently administered relative to meal intake in subjects with type 2 diabetes. Design. The study was a placebo‐controlled comparison with random assignment to treatment sequence. A 3‐h stepwise infusion of GLP‐1 (17 nmol) was started either at the onset of a standard meal (550 kCal) (A) or at 30 min (B) or 60 min (C) after the start of the meal. Setting. The study was conducted at a university hospital. Subjects. Eight patients with type 2 diabetes (four women and four men), age 62 ± 3.9 years (range 47–74 years), weight 79.8 ± 5.4 kg (range 62–104 kg), BMI 26.2 ± 1.3 kg m–2 (range 21–31 kg m–2), diabetes duration 10.5 ± 2.0 years (range 3–19 years) and HbA1c levels 6.1 ± 0.3% (range 4.7–7.7%) participated in the study. All patients were treated with oral sulphonylureas. Results. Glucagon‐like peptide‐1 significantly lowered postprandial glycaemia by a similar degree in all three situations versus the control meal (P < 0.05). Postprandial insulin levels were not different in the four experimental series, whereas the postprandial glucagon levels were significantly lowered by GLP‐1 in (A) and (B) (P < 0.03) but not in (C). Gastric emptying, as determined by the paracetamol test, was retarded by GLP‐1 only in (A) (P < 0.01), but not affected in (B) or (C). Conclusions. GLP‐1 reduced postprandial hyperglycaemia in subjects with type 2 diabetes regardless of administration at the onset of meal intake or at 30 or 60 min after start of meal intake, although the mechanism of the antidiabetogenic action of GLP‐1 depended on administration versus meal intake. Thus, when administered at the start of a meal, GLP‐1 was antidiabetogenic mainly through retarding gastric emptying, whereas when given at 30 or 60 min after meal ingestion, changes in islet hormone secretion seem to be predominant.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Self-citationNauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Self-citationGutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Self-citationTruncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
Self-citationEnergy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
Näslund, E., Barkeling, B., King, N., Gutniak, M., Blundell, J., Holst, J., Rössner, S., & Hellström, P. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800818 · Cited by 468
Self-citationTolessa, T., Gutniak, M., Holst, J. J., Efendic, S., & Hellström, P. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci942 · Cited by 139
Self-citation
Cited by
Abraham, E. J. (2002) · Endocrinology · doi:10.1210/en.143.8.3152 · Cited by 310
Alpha cell function in health and disease: influence of glucagon-like peptide-1
Dunning, B. E., Foley, J. E., & Ahrén, B. (2005) · Diabetologia · doi:10.1007/s00125-005-1878-0 · Cited by 271
Self-citationHellström, P. M., Näslund, E., Edholm, T., Schmidt, P. T., Kristensen, J., Theodorsson, E., Holst, J. J., & Efendic, S. (2008) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2007.01079.x · Cited by 160
Self-citationPamir, N., Lynn, F. C., Buchan, A. M. J., Ehses, J., Hinke, S. A., Pospisilik, J. A., Miyawaki, K., Yamada, Y., Seino, Y., McIntosh, C. H. S., et al. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00270.2002 · Cited by 126
Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus
León, D. D. D., Crutchlow, M. F., Ham, J.-Y. N., & Stoffers, D. A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.07.011 · Cited by 94
Metadata
- Authors
- Gutniak, M. K., Svartberg, J., Hellström, P. M., Holst, J. J., Adner, N., & Ahrén, B.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2001-07
- Volume
- 250
- Issue
- 1
- Pages
- 81-87
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W2088355739
- Cited by
- 27
- References
- 6
- FWCI
- 1.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antidiabetogenic action of glucagon‐like peptide‐1 related to administration relative to meal intake in subjects with type 2 diabetes. https://app.cochat.ai/papers/10.1046/j.1365-2796.2001.00862.x
- The paper
- Gutniak, M. K., Svartberg, J., Hellström, P. M., Holst, J. J., Adner, N., & Ahrén, B. (2001). Antidiabetogenic action of glucagon‐like peptide‐1 related to administration relative to meal intake in subjects with type 2 diabetes. Journal of Internal Medicine. https://doi.org/10.1046/j.1365-2796.2001.00862.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.